EC Number   |
Application |
Reference |
|---|
    6.3.1.5 | analysis |
method for measurement of allantoin in human serum. Serum allantoin is converted to allantoate by the action of allantoinase,and endogenous ammonia is simultaneously removed by the action of glutamine synthetase II. In the second step, L-methionine sulfoximine is used to inhibit glutamine synthetase II, and ammonia is liberated from allantoate by the activity of allantoate amidohydrolase. The ammonia is then converted to NAD by NAD synthetase. Subsequent action of glucose dehydrogenase and diaphorase acts to cycle the formed NAD between its oxidized and reduced forms, resulting in the production of WST-1 formazan, which is monitored at 450 nm. The assay standard curve is linear from 0 to 70 microM allantoin |
684413 |
| 6.3.1.5 | analysis |
the enzyme is used for an enzymatic cycling method for ammonia assay using a system consisting of three enzymes: EC 6.3.1.5, EC 1.1.1.47 and EC 1.6.99.2 |
661506 |
| 6.3.1.5 | analysis |
use of substrate 2-fluro-ATP as tool for 18F NMR-based activity screening |
692766 |
| 6.3.1.5 | drug development |
enzymes involved in NAD metabolism and synthesis are significant drug targets as NAD is a central player in several cellular processes |
-, 743959 |
| 6.3.1.5 | drug development |
NadE is a antimycobacterial drug target |
745674 |
| 6.3.1.5 | pharmacology |
NadE is a antimycobacterial drug target |
745674 |
| 6.3.1.5 | pharmacology |
preparation of isotopically labelled [13N]NAD+, a radiopharmaceutical designed for positron emission tomography, by the NAD+ synthetase immobilized on porous glass beads |
952 |
